{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-064786","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.315719+00:00","generated_at":"2026-06-11T21:30:49.165263+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oramed to acquire Scilex securities from Sorrento for $105M; provides $100M DIP loan","bullets":["Oramed will purchase Scilex common and preferred stock plus warrants from Sorrento for $105M total.","Consideration includes a dollar-for-dollar credit bid of outstanding obligations under a $100M replacement DIP facility.","Sorrento is in Chapter 11; transaction subject to Bankruptcy Court approval, auction, and closing by Sept 30, 2023.","Oramed is providing $100M senior secured super-priority DIP loan to Sorrento and Scintilla at 15% interest.","Oramed will receive rights to Scilex Series A preferred stock and governance control via proxy and call option."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-064786","json":"https://secwatch.observer/filing/0001213900-23-064786.json","markdown":"https://secwatch.observer/filing/0001213900-23-064786.md","text":"https://secwatch.observer/filing/0001213900-23-064786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023064786/0001213900-23-064786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023064786/ea183023-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:30:49.165263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ada491013a8f3afeb8c7ab8f7f59ac4e8a2eccc","claim":"ORAMED PHARMACEUTICALS INC. entered into Stock Purchase Agreement with Sorrento Therapeutics, Inc. valued at $105,000,000 (effective 2023-08-07).","evidence_excerpt":"entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”), between the Company and Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), pursuant to which, upon the terms and subject to the conditions set forth therein, the Company will acquire certain securities of Scilex Holding Company (“Scilex”) owned by the Seller","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023064786/0001213900-23-064786-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Sorrento Therapeutics, Inc."},{"label":"Value","value":"$105,000,000"},{"label":"Effective","value":"2023-08-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}